Update on the pathogenesis of Churg-Strauss syndrome

Clinical and Experimental Rheumatology

Volumn 21, Issue 6 SUPPL. 32, 2003, Pages

  Hellmich, Bernhard ^a,c   Ehlers, Stefan ^b   Csernok, Elena ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c Rheumaklinik Bad Bramstedt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BUDESONIDE; CARBAMAZEPINE; CYTOKINE; FAS ANTIGEN; FLUTICASONE; GLUCOCORTICOID; MACROLIDE; MONTELUKAST; NEUTROPHIL CYTOPLASMIC ANTIBODY; PRANLUKAST; SALMETEROL; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

APOPTOSIS; ASTHMA; CELL FUNCTION; CELL SECRETION; CELL SURVIVAL; CHURG STRAUSS SYNDROME; CYTOKINE RELEASE; DISEASE ACTIVITY; EOSINOPHILIA; GRANULOMATOSIS; HUMAN; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC VASCULITIS; T LYMPHOCYTE;

CHURG-STRAUSS SYNDROME; EOSINOPHILS; HUMANS;

EID: 0038221873     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. CHURG JSL: Allergic granulomatosis, allergic angiitis, and polyarteriitis nodosa. Am J Pathol 1951; 27: 277-301.
2. CHUMBLEY L, HARRISON E, DEREMEE R: Allergic granulomatosis and angiitis (Churg-Strauss syndrome): report and analysis of 30 cases. Mayo Clin Proc 1977; 52: 477-84.
3. LANHAM J, ELKON K, PUSEY C, HUGHES G: Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63: 65-81.
4. REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R, GUTFLEISCH J, PETER H, RASPE H, GROSS W: No difference in the incidences of vasculitides between north and south Germany: First results of the german vasculitis register. Rheumatology 2002; 41: 540-9.
5. WATTS R, SCOTT D: Classification and epidemiology of the vasculitides. Baillières Clin Rheumatol 1997: 11: 191-217.
6. WATTS R, CARRUTHERS D, SCOTT D: Epidemiology of systemic vasculitis: Changing incidence or definition. Semin Arthritis Rheum 1995: 25: 28-34.
7. WATTS R, LANE S, BENTHAM G, SCOTT D: Epidemiology of systemic vasculitis: a ten year study in the United Kingdom. Arthritis Rheum 2000: 43: 414-9.
8. LOUGHLIN J, COLE J, ROTHMAN K, JOHNSON E: Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol 2002; 88: 319-25.
9. CONRON M, BEYNON H: Churg-Strauss syndrome. Thorax 2000; 55: 870-7.
10. NOTH I, STREK M, LEFF A: Churg-Strauss syndrome. Lancet 2003; 361: 587-94.
11. LILLY C, CHURG A, LAZAROVICH M et al.: Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol 2002; 109: S1-20.
12. NAGASHIMA T, CAO B, TAKEUCHI N et al.: Clinicopathological studies of peripheral neuropathy in Churg-Strauss syndrome. Neuropathology, 2002; 22: 299-307.
13. GROSS W: Chur-Strauss-syndrome: Update on recent developments. Curr Opin Rheumatol 2002; 14: 11-4.
14. GUILLEVIN L, COHEN P, GAYRAUD M, LOHTE F, JAROUSSE B, CASUSS P: Churg-Strauss Syndrome: Clinical study and long-term follow-up of 96 patients. Medicine 1999: 78: 26-37.
15. SOLANS R, BOSCH J, PEREZ-BOCANEGRA C et al.: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001; 40: 763-71.
16. LEAVITT R, FAUCI A, BLOCH D et al.: The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
17. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Arthritis Rheum 1994; 37: 187-92.
18. RAO J, ALLEN N, PINCUS N: Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998: 129: 345-52.
19. ARBACH O, CSERNOK E, GROSS W, GAUSE A: Is the Churg-Strauss syndrome an ANCA-associated vasculitis ? Cleveland Clinic J Med 2002; 69: 173-4.
20. EUSTACE J, NADASDY T, CHOI M: The Churg-Strauss syndrome. J Am Soc Nephrol 1999; 10: 2048-55.
21. HELLMICH B, CSERNOK E, GROSS W: 20 years with ANCA (antineutrophil cytoplasmic antibodies): From seromarker to major pathogenic player in vasculitis. J Leuk Biol 2003 (in press).
22. WECHSLER M, FINN D, GUNAWARDENA D et al.: Churg-Strauss-Syndrome in patients receiving montelukast its treatment for asthma. Chest 2000: 117: 708-13.
23. WELLER P, PLAUT M, TAGGART V, TRONTELL A: The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108: 175-83.
24. CHURG A, BRALLAS M, CRONIN S, CHURG J: Formes frustes of Churg-Strauss syndrome. Chest 1995; 108: 320-3.
25. GEKELER V, ISE W, SANDERS K, ULRICH W, BECK J: The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995; 208: 345-52.
26. PRECHTL S, ROELLINGHOFF M, SCHEPER R, COLE S, DEELEY R, LOHOFF M: The multidrug resistance protein 1: A functionally important activation marker for murine Th1 cells. J Immunol 2000; 164: 754-61.
27. KIENE M, CSERNOK E, MULLER A, METZLER C, TRABANDT A, GROSS W: Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44: 469-73.
28. ROBBIANI D, FINCH R, JAGER D, MULLER W, SARTORELLI A, RANDOLPH G: The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3beta ELC)-dependent mobilization of dendrtitic cells to lymph nodes. Cell 2000; 103: 757-68.
29. POTTER M, FINCHER R, FINGER D: Eosinophilia in Wegener's granulomatosis. Chest 1999; 116: 1480-3.
30. GROSS W, SCHMITT W, CSERNOK E: ANCA and associated diseases. Immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 2001; 1993: 1-2.
31. HOFFMAN GS: Classification of the systemic vasculitides. Clin Exp Rheumatol 1998; 16: 111-5.
32. GROSS W, SCHNABEL A, TRABANDT A: New perspectives in pulmonary angiitis. From pulmonary angiitis and granulomatosis to ANCA associated vasculitis. Sarcoidosis Vasc Dif 2000; 17: 33-52.
33. GUILLEVIN L, AMOUROUX J, ARBEILLE B, BOURA R: Churg-Strauss angiitis. Arguments favoring the responsibility of inhaled antigens. Chest 1991: 100: 1472-3.
34. MANGER B, KRAPF F, GRAMATZKI M, NÜSSLEIN H, BURMESTER G, KRAULEDAT P, KALDEN J: IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Rheumatol 1985: 21: 369-73.
35. ROTHENBERG M: Eosinophilia. N Engl J Med 1988; 338: 1592-600.
36. CYR M, DENBURG J: Systemic aspects of allergic disease: The role of the bone marrow. Curr Opin Immunol 2001; 13: 727-32.
37. TSUKADIARA A, OKUBO Y, KITANO K et al.: Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc 1999; 20: 39-44.
38. SCHÖNERMARK U, CSERNOK E, TRABANDT A, HANSEN H, GROSS W: Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 2000; 18: 457-63.
39. MÜSCHEN M, WARSKULAT U, PERNIOK A et al.: Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 1999; 155: 915-25.
40. SCHNABEL A, CSERNOK E, BRAUN J, GROSS W: Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999; 54: 771-8.
41. MELLER S, JAGIELLO P, BORGMANN S, FRICKE H, EPPLEN J, GENCIK M: Novel SNPs in the CD18 gene validate the association with MPO-ANCA+ vasculitis. Genes Immun 2001: 2: 269-72.
42. GENCIK M, MELLER S, BORGMANN S, SITTER T, MENZES SAECKER A, FRICKE H, EPPLEN J: The association of CD18 alleles with anti-myeloperoxidase subtypes of ANCA-associated systemic vasculitides. Clin Immunol 2000; 94: 9-12.
43. MATSUMOTO K, APPIAH-PIPPIM, SCHLEIMER R, BICKEL C, ECK L, BOCHNER B: CD 44 and CD69 represent different types of cell-surface activation markers for human eosinophils. Am J Respir Cell Mol Biol 1998; 18: 860-6.
44. SCHMITT W, CSERNOK E, KOBAYASHI K, KLINKENBORG A, REINHOLD-KELLER E, GROSS W: Churg-Strauss syndrome. Serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 445-52.
45. TAI P, HOLT M, DENNY P, GIBBS A, WILLIAMS B, SPRY C: Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis: The Churg-Strauss syndrome. BMJ 1984; 289: 400-2.
46. DRAGE L, DAVIS M, DE CASTRO F et al.: Evidence for pathogenetic involvement of eosinophils and neutrophils in Churg-Strauss syndrome. J Am Acad Dermatol 2002; 47: 209-16.
47. PEEN E, HAHN P, WILLIAMS JR R, GLEICH G, KEPHART G: Churg-Strauss syndrome: Localization of eosinophil major basic protein in damaged tissues. Arthritis Rheum 2000; 43: 1897-900.
48. HATTORI N, ICHIMURA M, NAGAMATUS M et al.: Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122: 427-39.
49. FUJIOKA A, YAMAMOTO Y, TAKASU H et al.: The analysis of mRNA expression of cytokines from skin lesions in Churg-Strauss syndrome. J Endocrinol 1998; 25: 171-7.
50. GRIMALDI J, YU N, GRUNIG G et al.: Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leuk Biol 1999; 65: 846-53.
51. PLUMAS J, GUART V, ALDEBERT D: Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interluekin-2 receptor subunit. Eur J Immunol 1991; 21: 1265-8.
52. GRAU G, ROUX-LOMBARD P, GYSLER C, LAMBERT C, LAMBERT P, DAYER J: Serum cytokine changes in systemic vasculitis. Immunology, 1989; 68: 196-8.
53. ARBACH O, GROSS W, GAUSE A: Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206: 496-501.
54. ROMAGNANI P, ANNUNZIATO F, ROMAGNANI S: Pleiotropic biologic functions of CD30/CD30L. Does it contribute to negative selection in thymus ? The Immunologist 1998: 6: 137-41.
55. KUNKEL S, LUCAS N, STRIETER R, CHESNUE S: A model of granulomatous inflammation. Semin Respir Infect 1998; 13: 221-8.
56. CHTANOVA T, KEMP R, SUTHERLAND A, RONCHESE F, MACKAY C: Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells. J Immunol 2001; 15: 3057-63.
57. MEDZHITOV R, JANEWAY Jr C: Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
58. SPRINGER T: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
59. KINDLER V. SAPPINO A, GRAU G, PIGUET P, VASSALI P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989: 56: 731-40.
60. JOSEPH A, BOROS D: Tumor necrosis factor plays a role in Schistosoma mansoni egg-induced granulomatous inflammation. J Immunol 1993; 151: 5461-71.
61. SMITH D, HANSCH H, BANCROFT E, EHLERS S: T-cell-independent granuloma formation in response to Mycobacterium avium: Role of tumor necrosis factor-alpha and interferon-gamma. Immunology 1997; 92: 413-21.
62. AMIRIA P, LOCKSLEY R, PARSLOW T, SADICK M, RECTOR E, RITTER D, MCKERROW J: Tumour necrosis factor alpha restores granulomas and induced parasite egg-laying in schistosome-infected SCID mice. Nature 1992; 356: 604-7.
63. SHANG X, CHIU B, STOLBERG V, LUKACS N, KUNKEL S, MURPHY H, CHENSUE S: Eosinophil recruitment in type-2 hypersensitivity pulmonary granulomas: source and contribution of monocyte chemotactic protein-3. Am J Pathol 2002; 161: 257-66.
64. HOGABOAM C, BONE-LARSON C, LIPINSKI S, LUKACS N, CHENSUE S, STRIETER R, KUNKEL S: Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999: 163: 2193-201.
65. CHENSUE S, WARMINGTON K, RUTH J, SANGHI P, LINCOLN P, KUNKEL S: Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. J Immunol 1996; 157: 4602-8.
66. QUI B, FRAIT K, REICH F, KOMUNIECKI E, CHENSUE S: Chemokine expression dynamics in mycobacterial type-1) and shistosomal (type-2) antigen-elicited pulmonary granuloma formation. Am J Pathol 2001; 158: 1503-15.
67. CHENSUE S, LUKACS N, YANG T, SHANG X, RAIT K, KUNKEL S, UNG T, LIRA S: Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 2001; 193: 573-84.
68. RUTH J, WARMINGTON K, SHANG X, LINCOLN P, EVANOFF H, KUNKEL S. CHENSUE S: Interleukin 4 and 13 participation in mycobacterial (type-1) and schistosomal (type-2) antigen-elicted pulmonary granuloma formation: multiparameter analysis of cellular recruitment, chemokine expression and cytokine networks, Cytokine 2000; 12: 432-44.
69. CHENSUE S, WARMINGTON K, RUTH J, LUKACS N, KUNKEL S: Mycobacterial and schistosomal antigen-elicted granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks. J Immunol 1997; 159: 3565-73.
70. TATSIS E, SCHNABEL A, GROSS W: Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129: 370-4.
71. CHEN Y, WARMINGTON K, ALLENSPACH E, GERAD C, KUNKEL S, LUKACS N: Differential expression and cross-regulatory function of RANTES during mycobacterial (type-1) and shistosomal (type 2) antigen-elicted granulomatous inflammation. J Immunol 1999; 163: 165-73.